- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07615608
THERAVEX® REGENERA Tissue Care Plus for Hair Regeneration and Follicular Microenvironment Modulation
Prospective Translational Preclinical and Clinical Investigation Evaluating the Regenerative Effects and Safety of THERAVEX® REGENERA Tissue Care Plus on Hair Follicular Regeneration, Extracellular Matrix Modulation, and Follicular Microenvironment Optimization Using Preclinical Murine Models, Hair Transplantation Regenerative Support Protocols, and Exploratory Dermapen-assisted Scalp Regenerative Therapy in Alopecic Patients.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
This clinical investigation was designed to evaluate the clinical performance and safety of THERAVEX® REGENERA Tissue Care Plus as a supportive regenerative therapy in hair restoration and scalp regenerative procedures. Hair loss disorders and follicular density reduction are commonly associated with alterations in the scalp microenvironment, postoperative tissue stress, and impaired regenerative conditions that may influence hair restoration outcomes and postoperative recovery.
THERAVEX® REGENERA Tissue Care Plus is a sterile bioactive mineral-ionic formulation intended for local supportive use during regenerative scalp procedures. The investigational approach focused on evaluating its use as an adjunctive supportive therapy during follicular graft preparation, postoperative scalp care, and regenerative scalp support protocols under standardized clinical conditions.
The investigation included adult participants undergoing autologous hair transplantation procedures as well as participants presenting with non-scarring alopecic conditions requiring regenerative scalp treatment approaches. The investigational device was evaluated in combination with routine clinical hair restoration procedures and supportive regenerative scalp protocols, including topical scalp application, follicular graft conditioning, Dermapen-assisted scalp procedures, and mesotherapy-assisted scalp support techniques.
Clinical follow-up assessments included standardized scalp evaluation, digital photographic documentation, postoperative tissue response assessment, follicular density observation, tolerability monitoring, and longitudinal regenerative scalp follow-up. Participants were monitored throughout the predefined observation period according to standardized clinical evaluation schedules.
The study was conducted to further investigate the feasibility, tolerability, and clinical applicability of extracellular microenvironment supportive approaches in regenerative scalp care and hair restoration procedures.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Barcelona, Spanien, 08009
- Biointelligent Technology Syst
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
Adults aged 18 years or older Diagnosis of androgenetic alopecia, non-scarring alopecia, or follicular density reduction Candidates for hair restoration procedures or regenerative scalp therapy Clinically stable scalp condition at baseline evaluation Ability to comply with follow-up visits and study procedures Provision of written informed consent prior to participation
Exclusion Criteria:
Active scalp infection or inflammatory scalp disease Cicatricial alopecia or severe scalp pathology Uncontrolled systemic disease or unstable medical condition Pregnancy or breastfeeding Immunosuppressive therapy or systemic conditions potentially affecting tissue healing Known hypersensitivity to any component of the investigational device Participation in other investigational regenerative scalp therapies during the study period Inability to comply with follow-up procedures or study requirements
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: THERAVEX Regenerative Support
Sterile bioactive mineral-ionic regenerative solution used as supportive therapy during hair restoration and regenerative scalp procedures.
|
Conventional follicular transplantation and postoperative scalp care performed according to routine clinical practice.
|
|
Aktiv komparator: Standard Hair Restoration Care
Participants undergoing conventional hair restoration and postoperative scalp care procedures without THERAVEX® regenerative support.
|
Conventional follicular transplantation and postoperative scalp care performed according to routine clinical practice.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Follicular Density Assessment
Tidsramme: Baseline, 1 month, 3 months, 6 months, and 12 months
|
Quantitative evaluation of changes in follicular density following regenerative scalp support procedures using standardized trichoscopic imaging and digital follicular counting.
|
Baseline, 1 month, 3 months, 6 months, and 12 months
|
|
Scalp Tissue Response Assessment
Tidsramme: Baseline, 1 month, 3 months, 6 months, and 12 months]
|
Clinical evaluation of scalp tissue condition following regenerative scalp support procedures using standardized investigator-based assessment of tissue appearance, hydration, erythema, and overall scalp condition.
|
Baseline, 1 month, 3 months, 6 months, and 12 months]
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- Son-Med-24-7-PD
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Androgenetisk alopeci
-
Erasmus Medical CenterRekrutteringAlopecia Areata (AA) | Alopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU) | Alopecia Totalis/Universalis | Alopecia areata (og ophiasis)Holland
-
Hayat Abad Medical Complex, PeshawarIkke rekrutterer endnuAlopecia areata | Alopecia Universalis | Alopecia Totalis (AT)
-
Siriraj HospitalAfsluttetGenstridig Alopecia Totalis | Genstridig Alopecia UniversalisThailand
-
Aclaris Therapeutics, Inc.AfsluttetAlopecia Totalis (AT) | Alopecia Universalis (AU)Forenede Stater
-
Yale UniversityAfsluttetAlopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)Forenede Stater
-
University of MinnesotaColumbia UniversityRekrutteringAlopecia areata | Alopecia Totalis | Alopecia UniversalisForenede Stater
-
NanoAlvandAfsluttetAlopecia Areata (AA) | Alopecia Totalis/UniversalisIran, Islamisk Republik
-
M.D. Anderson Cancer CenterNational Alopecia Areata FoundationAktiv, ikke rekrutterendeAlopecia areata | Alopecia Totalis | Alopecia Universalis | Autoimmunt hårtab | Alopecia partialisForenede Stater
-
PfizerRekrutteringSvær alopecia areataSydkorea
-
Benha UniversityAfsluttetIndflydelse af NR3C1 rs41423247 (BclI) Polymorfisme på Sygdomsalvor i Alopecia Areata (NR3C1 and AA)Alopecia Areata (AA)Egypten
Kliniske forsøg med Standard Hair Restoration Care
-
Beijing BiotechRekrutteringEpitelial ovariecancer | Æggelederkarcinom | Primært peritonealt karcinom | Recidiverende eller refraktær sygdom efter standardbehandlingerKina
-
The First Affiliated Hospital of Air Force Medicial...RekrutteringRefraktær membranøs nefropatiKina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...RekrutteringKronisk lymfatisk leukæmi | Non-Hodgkin lymfom | Akut lymfatisk leukæmiForenede Stater
-
Kang YUCARsgen Therapeutics Co., Ltd.Aktiv, ikke rekrutterendeHepatocellulært karcinom | B-celle lymfom | Pancreascarcinom | Myelom | B-celle leukæmi | Adenocarcinom af Esophagogastric JunctionKina
-
Second Affiliated Hospital, School of Medicine,...Carbiogene Therapeutics Co. Ltd.Rekruttering
-
Hebei Senlang Biotechnology Inc., Ltd.The Second Hospital of Hebei Medical UniversityRekrutteringAkut lymfoblastisk leukæmi i barndommenKina
-
The Second Affiliated Hospital of Henan University...Xuzhou Medical University; Xinqiao Hospital of ChongqingUkendtTilbagevendende voksent diffust storcellet lymfom | Tilbagevendende grad 1 follikulært lymfom | Tilbagevendende grad 2 follikulært lymfom | Tilbagevendende grad 3 follikulært lymfom | Tilbagevendende kappecellelymfom | Hæmatopoietisk/lymfoid kræft | Voksen akut lymfatisk leukæmi i remission | B-celle... og andre forholdKina
-
Beijing Immunochina Medical Science & Technology...Ikke rekrutterer endnuNeoplasmer | Neoplasmer efter histologisk type | Lymfom | Lymfoproliferative lidelser | Lymfom, kappecelle
-
Xijing HospitalXi'An Yufan Biotechnology Co.,LtdRekrutteringLymfom, B-celle | CD19 positiv | Leukæmi Lymfocytisk Akut (ALL) ved tilbagefald | Leukæmi Lymfocytisk Akut (Alle) RefraktærKina
-
First Affiliated Hospital of Wenzhou Medical UniversitySecond Affiliated Hospital of Nanchang University; Hrain Biotechnology...UkendtHæmatopoietisk/lymfoid kræft | Voksen akut lymfatisk leukæmi i remission | B-celle kronisk lymfatisk leukæmi | Refraktær kronisk lymfatisk leukæmi | B-celle akut lymfoblastisk leukæmi hos voksneKina